A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer Patients - A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer Patients

Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine0 sites27 target enrollmentDecember 8, 2010

ConditionsObjective of the study is to investigate efficacy and safety of Erlotinib for previously treated non-small cell lung cancer patients.

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Objective of the study is to investigate efficacy and safety of Erlotinib for previously treated non-small cell lung cancer patients.
Sponsor: Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine
Enrollment: 27
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 8, 2010

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\) Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, or drug\-induced pneumonitis. 2\) Patients with massive pleural or pericardial effusion,or ascites. 3\) Patients with active severe infections. 4\) Cases with past history of administration of HER related agents(gefitinib,trastuzumab,lapatinib,cetuximab). 5\) Impossible cases with oral administration. 6\) Patients with active opthalmological disease. 7\) Pregnancy or lactation. 8\) Patients with symptomatic brain metastasis. 9\) Patients with active concomitant malignancy. 10\) Patients with uncontrollabe diabetes mellitus. 11\) Patients with uncontrollable complications. 12\) Inappropriate patients for this study judged by the physicians.